iBio (IBIO) Stock Price, News & Analysis

0.00 (0.00%)
(As of 04/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
98,539 shs
Average Volume
3.08 million shs
Market Capitalization
$6.61 million
P/E Ratio
Dividend Yield
Price Target

About iBio

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

IBIO Stock Price History

IBIO Stock News Headlines

See More Headlines
Receive IBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End

Industry, Sector and Symbol

Current Symbol
Year Founded


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$2.38 million
Book Value
$15.15 per share


Free Float
Market Cap
$6.61 million
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Martin B. Brenner D.V.M. (Age 53)
    Ph.D., CEO & Chief Scientific Officer
    Comp: $577.31k
  • Mr. Felipe Duran (Age 44)
    Chief Financial Officer
    Comp: $1.07M
  • Stephen Kilmer
    Investor Relations Officer
  • Mr. Marc Banjak J.D.
    General Counsel
  • Mr. Robert B. Kay (Age 84)
    Interim Secretary & Interim Treasurer
    Comp: $92.69k

IBIO Stock Analysis - Frequently Asked Questions

Are investors shorting iBio?

iBio saw a increase in short interest in March. As of March 31st, there was short interest totaling 161,700 shares, an increase of 172.7% from the March 15th total of 59,300 shares. Based on an average daily volume of 3,680,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 1.9% of the shares of the stock are sold short.
View iBio's Short Interest

How were iBio's earnings last quarter?

iBio, Inc. (NYSEAMERICAN:IBIO) posted its quarterly earnings data on Friday, February, 9th. The company reported ($2.42) EPS for the quarter.

What other stocks do shareholders of iBio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iBio investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Heat Biologics (HTBX), Novavax (NVAX), Dynavax Technologies (DVAX), Co-Diagnostics (CODX), Nokia Oyj (NOK) and Moderna (MRNA).

How do I buy shares of iBio?

Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:IBIO) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners